The US has denied a bid to allow MDMA, commonly known as ecstasy or molly, to be used in the treatment for post-traumatic stress disorder (PTSD).
The US Food and Drug Administration (FDA) was examining the psychedelic drug made by Lykos Therapeutics to treat the mental health disorder in combination with talk therapy.
When they deny something like this because of claimed flaws in study, do they give detailed descriptions of the flaws and help (maybe for a fee) the petitioner make a new study?
Or do they leave it vague enough so they can just perpetually say it’s flawed?